Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 NF[yfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSwMlUh|ryP Mln0O|IhcA>? MYTEUXNQ M1zRZWlEPTB;MD6wOEDPxE1? NX[2SmZkOjZzM{[2PFQ>
LS174T MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHRNE42KM7:TR?= NXrYeWhpPzJiaB?= NFPYT2RFVVOR MY\JR|UxRTBwMEWg{txO MVGyOlE{PjZ6NB?=
T84 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfoNE42KM7:TR?= NEezW5g4OiCq MVfEUXNQ NXWzdopPUUN3ME2wMlA6KM7:TR?= M3S3dVI3OTN4Nki0
LS180 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\jNVAvPSEQvF2= MVS3NkBp MWHEUXNQ MlXpTWM2OD1zIN88US=> NXXGR3c1OjZzM{[2PFQ>
SW948 M1LCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMlUh|ryP NFTLbFE4OiCq MYrEUXNQ NH3sWmJKSzVyPUGg{txO NXK5dJBjOjZzM{[2PFQ>
HCT15 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:wMlUh|ryP NETiOWs4OiCq NIDvbFNFVVOR NF[zfI1KSzVyPECuOEDPxE1? MlKwNlYyOzZ4OES=
DLD-1 NWnFRVRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTzVoRiOC53IN88US=> M3S3dVczKGh? NXzI[o5wTE2VTx?= MXrJR|UxRDBwODFOwG0> M3fuflI3OTN4Nki0
MIP-101 M33xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG4UogxNjVizszN NF;yRmk4OiCq NGX1W4hFVVOR NVqyTG1JUUN3ME2xJO69VQ>? MXKyOlE{PjZ6NB?=
SNU1544 M1r3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXUNpExNjVizszN NF;Lcmk4OiCq MoPRSG1UVw>? NYDPOXR1UUN3ME2xJO69VQ>? MorINlYyOzZ4OES=
OCI-Ly10 MnfHR5l1d3SxeHnjJGF{e2G7 NXPiW4NlPzJiaB?= MULEUXNQ Ml;kTWM2OD1yLkC1PEDPxE1? M1q3NVI2QDd6M{Ox
SU-DHL2 NGrZOY1EgXSxdH;4bYMhSXO|YYm= NH3R[4c4OiCq M{nmc2ROW09? NXvkSIo2UUN3ME2wMlAyKM7:TR?= M4m1R|I2QDd6M{Ox
OCI-LY7 M4X0NGN6fG:2b4jpZ{BCe3OjeR?= MX:3NkBp Mly5SG1UVw>? M3HJOWlEPTB;MD6wPFEh|ryP NWSyc4pnOjV6N{izN|E>
SU-DHL6 NYnaUVNnS3m2b4TvfIlkKEG|c3H5 M1\mWFczKGh? Ml7RSG1UVw>? NXPwOo5UUUN3ME2wMlQ5OiEQvF2= M2\sR|I2QDd6M{Ox
Jeko-1 NVjDT|RNS3m2b4TvfIlkKEG|c3H5 NFz1WHE4OiCq MlPVSG1UVw>? M1jhdWlEPTB;MD6wNlkh|ryP MkntNlU5Pzh|M{G=
JVM-2 NXfhV4VxS3m2b4TvfIlkKEG|c3H5 NUD3TlY1PzJiaB?= NXjUOoRWTE2VTx?= NYj1N49sUUN3ME2wMlAyKM7:TR?= NGHLS2ozPTh5OEOzNS=>
Rec-1 Ml3UR5l1d3SxeHnjJGF{e2G7 MWG3NkBp NIPGXoRFVVOR NELtXFZKSzVyPUCuNFg4KM7:TR?= M1T5e|I2QDd6M{Ox
Z-138 MmHqR5l1d3SxeHnjJGF{e2G7 MnzFO|IhcA>? NUG2eG9mTE2VTx?= Mkf6TWM2OD1yLkCxN{DPxE1? NYDEcXBpOjV6N{izN|E>
H9 NGXhcWdEgXSxdH;4bYMhSXO|YYm= MmrjO|IhcA>? NYD1UnA4TE2VTx?= NIjne5NKSzVyPUCuOkDPxE1? M{nKfFI2QDd6M{Ox
HH MUfDfZRwfG:6aXOgRZN{[Xl? M4joV|czKGh? NUHrPFc4TE2VTx?= NEi3cVVKSzVyPUCuO{DPxE1? Mm\XNlU5Pzh|M{G=
DND41 M3j2eWN6fG:2b4jpZ{BCe3OjeR?= NUOxdYNpPzJiaB?= M3S2ZmROW09? NFTqPXlKSzVyPUCuNUDPxE1? M3ezVVI2QDd6M{Ox
CCL119 NH\DZZREgXSxdH;4bYMhSXO|YYm= MXW3NkBp NFnmZ2FFVVOR M3XPZWlEPTB;MD6wOlIh|ryP MU[yOVg4QDN|MR?=
J.Cam 1.6 NWq4TpRtS3m2b4TvfIlkKEG|c3H5 M1KycVczKGh? M4Drd2ROW09? M2nXeGlEPTB;MD6xNFUh|ryP NI[5bIYzPTh5OEOzNS=>
Sup-T1 NV65TlRZS3m2b4TvfIlkKEG|c3H5 MV:3NkBp NUH3epZuTE2VTx?= MkDtTWM2OD1{LkG0NkDPxE1? MV[yOVg4QDN|MR?=
Tib 152 NGnuPZREgXSxdH;4bYMhSXO|YYm= NWDZUoF4PzJiaB?= MlLWSG1UVw>? M1fHdGlEPTB;MD64JO69VQ>? MmrZNlU5Pzh|M{G=
MCF7 MofMSpVv[3Srb36gRZN{[Xl? MYK1JO69VQ>? M4nQSVI1KGh? M{j5cWROW09? MkDHTY5lfWOnczDHNk9OKGG{cnXzeC=> MV2yOVg{PDRyMR?=
MDA-MB-231 MnrDSpVv[3Srb36gRZN{[Xl? MoXqOUDPxE1? NF7Vd2kzPCCq M4\nSGROW09? NEjrXoRKdmS3Y3XzJGc{N01iYYLy[ZN1 NWr3ZnZ[OjV6M{S0NFE>
MCF7 M3jYcGZ2dmO2aX;uJGF{e2G7 MX61JO69VQ>? M1nEbFI1KGh? MnvOSG1UVw>? MXvE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ NFzkN|UzPTh|NESwNS=>
MCF7 NUnHSY55TnWwY4Tpc44hSXO|YYm= NFLoPIU2KM7:TR?= M2LyblI1KGh? MWrEUXNQ NEfjPY5F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? NYfBfmNqOjV6M{S0NFE>
MCF7 NEPnXFhHfW6ldHnvckBCe3OjeR?= NV;IXJc2PSEQvF2= M1Wxb|I1KGh? NUTlSmZHTE2VTx?= M3HRSmRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG= NH;HN3IzPTh|NESwNS=>
MCF7 NIKxS|hHfW6ldHnvckBCe3OjeR?= MmnKOUDPxE1? NHHnZ2YzPCCq NVjuTJhQTE2VTx?= MWLJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> M1rLV|I2QDN2NECx
MCF7 NVzHfpN5TnWwY4Tpc44hSXO|YYm= MUe1JO69VQ>? NGizXWszPCCq MlrrSG1UVw>? M2G0Tmlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= MmPyNlU5OzR2MEG=
MDA-MB-231 MoXrSpVv[3Srb36gRZN{[Xl? M{\WOFUh|ryP NGS4NmgzPCCq MmqxSG1UVw>? MYTE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ NIfqUZMzPTh|NESwNS=>
MDA-MB-231 Ml7zSpVv[3Srb36gRZN{[Xl? MmnvNUDPxE1? M336VFI1KGh? NYX6fHduTE2VTx?= MYjJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> NGDFPYIzPTh|NESwNS=>
MDA-MB-231 MkK3SpVv[3Srb36gRZN{[Xl? MVq1JO69VQ>? M1Xvd|I1KGh? M3XDdGROW09? MmH4SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?= MnLYNlU5OzR2MEG=
MDA-MB-231 NIH4OZdHfW6ldHnvckBCe3OjeR?= MVK1JO69VQ>? NYDXeIp5OjRiaB?= M4fvWWROW09? MWPJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> NF\Ld3ozPTh|NESwNS=>
MDA-MB-231 M{TVO2Z2dmO2aX;uJGF{e2G7 NEXQZnM2KM7:TR?= M1PmWlI1KGh? NIfWVGJFVVOR M{PuN2lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= M17uXlI2QDN2NECx
MDA-MB-231 NWj2[pBpTnWwY4Tpc44hSXO|YYm= M4nSflUh|ryP Mnj5NlQhcA>? MonBSG1UVw>? NYToeohlUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJA2Ow>? NFjiPZEzPTh|NESwNS=>
MCF7 NEPzelRCeG:ydH;zbZMhSXO|YYm= NIPa[2c2KM7:TR?= M2PNRVI1KGh? NWfYWmY1TE2VTx?= NVj1WVBzUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= NX3vO5N{OjV6M{S0NFE>
MDA-MB-231 NGHKWmxCeG:ydH;zbZMhSXO|YYm= NInIcog2KM7:TR?= NV63dYt{OjRiaB?= MlzlSG1UVw>? NYnOVm5OUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= Mnq3NlU5OzR2MEG=
MCF7 NEHabpVHfW6ldHnvckBCe3OjeR?= NXW4UYRuOSEQvF2= NXvYOIJ{PzJiaB?= M{fVd2ROW09? MlO3TY5lfWOnczDheZRweGijZ3njJIRm[XSq NYfWWol1OjV6M{S0NFE>
MDA-MB-231 MUXGeY5kfGmxbjDBd5NigQ>? M3nNWFEh|ryP M2XJXFczKGh? MoDJSG1UVw>? NV\WbWRmUW6mdXPld{BifXSxcHjh[4lkKGSnYYTo NYe1SotROjV6M{S0NFE>
U-2 OS M{K1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi1NEDPxE1? M13v[FI1KGh? M3nlW2ROW09? M3nEfmlEPTB;MU[uOkDPxE1? MnXmNlU4QTJ6MUG=
MG-63 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\QOVAh|ryP M1y3VVI1KGh? Mn7QSG1UVw>? MnTjTWM2OD17LkWg{txO NUHNSng2OjV5OUK4NVE>
U-2 OS NEH2NmZCeG:ydH;zbZMhSXO|YYm= MYi1JO69VQ>? MkW5NlQhcA>? Ml\BSG1UVw>? MVnJcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo MWiyOVc6OjhzMR?=
MG-63 M2DOSmFxd3C2b4Ppd{BCe3OjeR?= MorvOUDPxE1? MYmyOEBp MWrEUXNQ NFLGbXZKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NHLMcm4zPTd7MkixNS=>
U-2 OS NUnpc4c4TnWwY4Tpc44hSXO|YYm= MkPQOUDPxE1? MVeyOEBp MX\EUXNQ MonEVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp NH\teZozPTd7MkixNS=>
MG-63 NEToT2RHfW6ldHnvckBCe3OjeR?= M3jOZ|Uh|ryP MYqyOEBp NEDnWWRFVVOR NGrC[2NRem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NUPac5c3OjV5OUK4NVE>
PANC-1 MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojOOVAh|ryP MWiyOEBp M1rFOWROW09? Mly0TWM2OD15LkGg{txO NUiwUWhKOjV4M{KyNlU>
BxPC-3 M{fU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDlOVAh|ryP NETVWpczPCCq M1rhWWROW09? MXTJR|UxRTZwODFOwG0> NF:xOJozPTZ|MkKyOS=>
PANC-1 NV\ZOIp[TnWwY4Tpc44hSXO|YYm= NIXkS3Y2KM7:TR?= NFz5R|UzPCCq NH7IeZBFVVOR Ml[zTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckBIOi:PIIDoZZNm MoP2NlU3OzJ{MkW=
BxPC-3 NYnXbI1xTnWwY4Tpc44hSXO|YYm= MV61JO69VQ>? M17hb|I1KGh? MUHEUXNQ M3rRSmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? NVmzXGVJOjV4M{KyNlU>
PANC-1 MWrGeY5kfGmxbjDBd5NigQ>? MUm1JO69VQ>? NIDvSG0zPCCq M3v0[2ROW09? NVXOU21lUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NYP5UY9vOjV4M{KyNlU>
BxPC-3 MlH2SpVv[3Srb36gRZN{[Xl? NVfVenMzPSEQvF2= M4niWlI1KGh? MYXEUXNQ NUjoNXBrUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MoLyNlU3OzJ{MkW=
SKOV3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjFcYkyODBizszN NIXFNoozPCCq M4\HUWROW09? NXK2b3NjUUN3ME2yNE41QCEQvF2= NXi0eY1kOjV4MkS3OVA>
OVCAR4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNFAh|ryP M2XkZlI1KGh? Ml3kSG1UVw>? MV3JR|UxRTJ{LkGzJO69VQ>? NVnlNpJQOjV4MkS3OVA>
SKOV3 MUTGeY5kfGmxbjDBd5NigQ>? NXfpNWNLPSEQvF2= NFP4bVA4OiCq NHvSWYdFVVOR NH\LOIdKdmS3Y3XzJGczN01iYYLy[ZN1 NV7PN3U1OjV4MkS3OVA>
OVCAR4 NXzJ[HFjTnWwY4Tpc44hSXO|YYm= NHLvbZI2KM7:TR?= MUO3NkBp NXrvb2hwTE2VTx?= NUfqfm1jUW6mdXPld{BIOi:PIHHydoV{fA>? MmXiNlU3OjR5NUC=
SKOV3 M{\hXWFxd3C2b4Ppd{BCe3OjeR?= MYW1JO69VQ>? Mn7tNlQhcA>? M2XmOGROW09? MXnJcoR2[2W|IHHwc5B1d3Orcx?= M4LIbVI2PjJ2N{Ww
OVCAR4 MUTBdI9xfG:|aYOgRZN{[Xl? Mme1OUDPxE1? NXfOfFM3OjRiaB?= MW\EUXNQ NF3vTphKdmS3Y3XzJIFxd3C2b4Ppdy=> NHXwPGgzPTZ{NEe1NC=>
AGS NVi4VJJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L2TVI2KM7:TR?= M{LPNlI1KGh? MY\EUXNQ MUfJR|UxRTF7LkC5JO69VQ>? MVqyOVYxQTl{Mx?=
NCI-N78 NIfjWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WxblI2KM7:TR?= M4[0SlI1KGh? MXXEUXNQ MnH3TWM2OD1{Nj6zN{DPxE1? M4DoRlI2PjB7OUKz
AGS M{jKVWFxd3C2b4Ppd{BCe3OjeR?= MlXPOUDPxE1? MnvGNlQhcA>? MkjHSG1UVw>? NUDZR5pQUW6mdXPld{BieG:ydH;zbZM> NEmzUIQzPTZyOUmyNy=>
NCI-N78 MmW1RZBweHSxc3nzJGF{e2G7 MkS3OUDPxE1? M{\rfFI1KGh? NGf2fJVFVVOR NWfQSmM5UW6mdXPld{BieG:ydH;zbZM> NIHufnozPTZyOUmyNy=>
AGS MlzwSpVv[3Srb36gRZN{[Xl? NWT0UolNPSEQvF2= MkPaNlQhcA>? MVvEUXNQ MmT6TY5lfWOnczD0bIUh[XW2b4DoZYd6 M1Pq[lI2PjB7OUKz
NCI-N78 MoXpSpVv[3Srb36gRZN{[Xl? NVfPNJV5PSEQvF2= Mn;oNlQhcA>? MVzEUXNQ NYLQ[Il[UW6mdXPld{B1cGViYYX0c5Bp[We7 NWrCcm1nOjV4MEm5NlM>
HSC-3 NVzQbpltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxJO69VQ>? NIPzc|c1QCCq MYTJR|UxRTBwNUSg{txO MXmyOVM3PjF2Mx?=
GB30 NFPCOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxJO69VQ>? MXO3JIQ> Ml;uSG1UVw>? NIfIR3RKSzVyPUCuNFEyKM7:TR?= NWX6NGVXOjVzME[0Nlg>
GB9 NID0PWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCxJO69VQ>? M3G0Olch\A>? MoTiSG1UVw>? NHTDToJKSzVyPUCuNFI1KM7:TR?= NGPMWZkzPTFyNkSyPC=>
GB169 M3HsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqxJO69VQ>? MlHoO{Bl NXi0PY9{TE2VTx?= NE\0VHRKSzVyPUCuNFMzKM7:TR?= NFn2emMzPTFyNkSyPC=>
T24 MlXwSpVv[3Srb36gRZN{[Xl? NETIbZMyKM7:TR?= NWq1dYlFPDhiaB?= M3X1dmROW09? MorETY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MWiyN|QxOzZ|Mx?=
RT4 NHfGcWJHfW6ldHnvckBCe3OjeR?= NFfDRY8yKM7:TR?= MX60PEBp MXXEUXNQ M2PKTWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NYjVUmZKOjN2MEO2N|M>
UM-UC-3 NXWzbXJpTnWwY4Tpc44hSXO|YYm= NGjQO5EyKM7:TR?= MX60PEBp MnnhSG1UVw>? MUDJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NHfWeXMzOzRyM{[zNy=>
T24 MlLBRZBweHSxc3nzJGF{e2G7 Ml;HN{4yPiEQvF2= NXy3OpNuQTZiaB?= NXnMOZh{TE2VTx?= MWDJR|UxRTBwMEOwOkDPxE1? NVywWmZYOjN2MEO2N|M>
RT4 NXvDZW5wSXCxcITvd4l{KEG|c3H5 NUXrPZN3Oy5zNjFOwG0> NHWzSlM6PiCq NYfJRZBJTE2VTx?= NInmOnRKSzVyPUCuNVE6QCEQvF2= Mom5NlM1ODN4M{O=
UM-UC-3 NEDYdpJCeG:ydH;zbZMhSXO|YYm= NF7zd3Y{NjF4IN88US=> MVi5OkBp M3[yS2ROW09? Mn;ZTWM2OD1yLkC0OFkh|ryP M2G5OFI{PDB|NkOz
OVCAR-5 MXjGeY5kfGmxbjDBd5NigQ>? M{HWRlUxKG6P NY\adGRwUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= MmTJNlM{OzR|Mke=
SKOV3ip2 NXTNbnlITnWwY4Tpc44hSXO|YYm= NEjXWFk2OCCwTR?= NHPqTHNKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= MVuyN|M{PDN{Nx?=
S462 NGDBW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSxNFAh|ryP M4m5eVczKGh? NE\WSpZFVVOR MkT5RZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? Mom3NlM{OjhzMUS=
2884 NFrRbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfEbHlxOTByIN88US=> M2ThXFczKGh? NUDYdnlFTE2VTx?= NETsT|RCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NIDqTnozOzN{OEGxOC=>
2885 NGfU[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzVc3k{OTByIN88US=> MV63NkBp NEnP[XRFVVOR NWjWWpd5SXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= Mn;SNlM{OjhzMUS=
CRL-2396 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVexNFAh|ryP NXfxRmpqf2G2ZYK= MV\JR|UxRTBwMEmyJO69VQ>? NWjWXYxJOjNzNUO1NlQ>
TIB-48 NVnBV5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfINVAxKM7:TR?= NFvxdoV4[XSnch?= NFvPSmhKSzVyPUCuNFg5KM7:TR?= MXOyN|E2OzV{NB?=
CRL-2396 MVzDfZRwfG:6aXOgRZN{[Xl? NFLPcYIyKM7:TR?= MUe0PEBp M4fMcZdifGW{ MnvRTY5lfWOnczDhdI9xfG:|aYO= M17KV|I{OTV|NUK0
TIB-48 MYrDfZRwfG:6aXOgRZN{[Xl? NWLQSXFUOSEQvF2= M1PLZ|Q5KGh? NFzrepZ4[XSnch?= M1fBVGlv\HWlZYOgZZBweHSxc3nz NHHGU|MzOzF3M{WyOC=>
AGS NHKwfIxEgXSxdH;4bYMhSXO|YYm= MUKwMlUh|ryP NFfmfYQzPCCq MXjEUXNQ M{Oze2Rm[3KnYYPld{Bk\WyuIIP1dpZqfmGu MoLRNlI6PzJ4MUG=
FLO-1 NUTGdnFJS3m2b4TvfIlkKEG|c3H5 NYnQVphjOC53IN88US=> M1\yXVI1KGh? M2W4[mROW09? MV3E[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? M1jPeFIzQTd{NkGx
OE33 NYC0UoUyS3m2b4TvfIlkKEG|c3H5 MlXINE42KM7:TR?= M{XNV|I1KGh? NWPQWIJUTE2VTx?= M1PyOWRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu NWHqSWM5OjJ7N{K2NVE>
SKLMS MnSyR5l1d3SxeHnjJGF{e2G7 M4\Jflc2KG6P NGnyfWg6PiCq NITPe3JKdmS3Y3XzJIFxd3C2b4Ppdy=> M3j5c|IzQDJzOUm3
Leio285 M2PGW2N6fG:2b4jpZ{BCe3OjeR?= NVH2dWhMPzVibl2= MXS5OkBp MXrJcoR2[2W|IHHwc5B1d3Orcx?= MkL0NlI5OjF7OUe=
Mes-Sa MV3DfZRwfG:6aXOgRZN{[Xl? M4ryO|c2KG6P M3TsVFk3KGh? MnLtTY5lfWOnczDhdI9xfG:|aYO= M1\ycVIzQDJzOUm3
DAOY MmL4R5l1d3SxeHnjJGF{e2G7 NFTmTlEyOCEQvF2= NGfwXIk4OiCq NH;XNFJFVVOR NGHRc3hKSzVyPUCuNFQh|ryP MVOyNlY3QTN|NR?=
IMR32 MlG1R5l1d3SxeHnjJGF{e2G7 MmjtNVAh|ryP Mki0O|IhcA>? MUjEUXNQ MUTJR|UxRTBwMEOg{txO MnfFNlI3Pjl|M{W=
Molt-4 NUjJXZNUS3m2b4TvfIlkKEG|c3H5 NUjESVR3OTBizszN NX\VcHRSPzJiaB?= M3[we2ROW09? MlLZTWM2OD1yLkCyJO69VQ>? NWrJTVNvOjJ4NkmzN|U>
MOLM-13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X6PVMh|ryP MkXaO|IhcA>? NWLybmY2TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> M3\DelIzPDh6MkS5
HL-60 M1Tacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXezJO69VQ>? NHjE[JU4OiCq Ml[1SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= M4[3NVIzPDh6MkS5
MV4-11 M3jkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W1bVMh|ryP MnLaO|IhcA>? NWmzWnJvTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> M1LyOVIzPDh6MkS5
SKM-1 NXrVXFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXzTHQ{KM7:TR?= NGXIRno4OiCq MknPSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NYjPXo9FOjJ2OEiyOFk>
SH2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XSSVMh|ryP M4HGdVczKGh? Mne2SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NGXZNY0zOjR6OEK0PS=>
NOMO-1 NF\w[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETKZ5o{KM7:TR?= NXPnR3RCPzJiaB?= MWXEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NVPTeVF6OjJ2OEiyOFk>
OCL-AML2 NYTCUpg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWizJO69VQ>? NVrZfnN4PzJiaB?= NIfRWXBFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M1nDPFIzPDh6MkS5
PL-21 M4DveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PmSVMh|ryP MWO3NkBp MnX4SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MXqyNlQ5QDJ2OR?=
KG-1 M{D1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW0NmdmOyEQvF2= MU[3NkBp M4DUW2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NEfHfZMzOjR6OEK0PS=>
A172 M4\l[mN6fG:2b4jpZ{BCe3OjeR?= M2q3cFExOCEQvF2= MU[yOEBp MWPEUXNQ M{fafWlEPTB;MD6xNlAh|ryP NEHVTZIzOjJ5NEO5PS=>
U87 M{Due2N6fG:2b4jpZ{BCe3OjeR?= NFPZTJgyODBizszN MoTtNlQhcA>? NFzFbnFFVVOR MVPJR|UxRTBwMUC1JO69VQ>? MlL6NlIzPzR|OUm=
U251 MUDDfZRwfG:6aXOgRZN{[Xl? NVr6Wm94OTByIN88US=> MUmyOEBp NWXBb|ZvTE2VTx?= MWXJR|UxRTBwMUCwJO69VQ>? NFXWSHIzOjJ5NEO5PS=>
T98 M4nve2N6fG:2b4jpZ{BCe3OjeR?= NEXqdGkyODBizszN M1GySFI1KGh? M1HQSWROW09? NGTrd5BKSzVyPUCuNVI2KM7:TR?= MkfjNlIzPzR|OUm=
LN18 MUfDfZRwfG:6aXOgRZN{[Xl? NFXSdZgyODBizszN MU[yOEBp MXrEUXNQ NGPFR3NKSzVyPUCuNlExKM7:TR?= M2rz[VIzOjd2M{m5
LN443 MYDDfZRwfG:6aXOgRZN{[Xl? M3H0R|ExOCEQvF2= MWqyOEBp M2\5ZWROW09? MnGyTWM2OD1yLkKyNEDPxE1? NVHueVRTOjJ{N{SzPVk>
HF66 NX25UmtsS3m2b4TvfIlkKEG|c3H5 NFfKSGoyODBizszN NH33d|MzPCCq NF3WXJBFVVOR MnjKTWM2OD1yLkKyOUDPxE1? M4Hj[VIzOjd2M{m5
HF2303 NF;HTZJEgXSxdH;4bYMhSXO|YYm= MUGxNFAh|ryP NXvEUYlWOjRiaB?= NID3T5dFVVOR NHW1SHhKSzVyPUCuNFYxKM7:TR?= M2LmdFIzOjd2M{m5
HF2359 M3fCVGN6fG:2b4jpZ{BCe3OjeR?= MXuxNFAh|ryP MVyyOEBp NX3XcFJ7TE2VTx?= MmXaTWM2OD1yLkC2NEDPxE1? NEXETFQzOjJ5NEO5PS=>
HF2414 MUHDfZRwfG:6aXOgRZN{[Xl? MXSxNFAh|ryP MWmyOEBp MmrrSG1UVw>? MWfJR|UxRTBwMEiwJO69VQ>? MlfvNlIzPzR|OUm=
A-673 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LyTlExKM7:TR?= M3iwfVk3KGh? MVLEUXNQ M3n2SmlEPTB;MD6wN|Ih|ryP M2n3NFIyPDR6NUmx
TC-32 NXXWSFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7iNVAh|ryP NEnsV4g6PiCq MWnEUXNQ MX;JR|UxRTBwMEO5JO69VQ>? MX2yNVQ1QDV7MR?=
TC-71 NFTSVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj3NWpEOTBizszN MYC5OkBp MnXESG1UVw>? NW\BV4FXUUN3ME2wMlExOiEQvF2= NYrO[JhnOjF2NEi1PVE>
SK-N-MC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f5N|ExKM7:TR?= NHnJOFU6PiCq Mmr2SG1UVw>? MV;JR|UxRTBwMEeyJO69VQ>? M1X6WFIyPDR6NUmx
CHLA-9 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLZUXIyOCEQvF2= MlXxPVYhcA>? NYnnN4JwTE2VTx?= NH;TRpBKSzVyPUCuNFE5KM7:TR?= MmDLNlE1PDh3OUG=
CHLA-10 NYfVfJl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHSTW1TOTBizszN MoXUPVYhcA>? M{m3NmROW09? MnKzTWM2OD1yLkC2NEDPxE1? NH;COJUzOTR2OEW5NS=>
CHLA-25 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PpTlExKM7:TR?= MmXOPVYhcA>? MYTEUXNQ M{fnVWlEPTB;MD6xOlgh|ryP NX;GUnhyOjF2NEi1PVE>
CHLA-32 M4XTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zFflExKM7:TR?= MWO5OkBp MVvEUXNQ NWPHVmVrUUN3ME2wMlE{PiEQvF2= NXvkc4NtOjF2NEi1PVE>
CHLA-56 NWfxXXZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvlNVAh|ryP M1\5blk3KGh? NHPJfoJFVVOR M4rlbWlEPTB;MUCg{txO MmXCNlE1PDh3OUG=
CHLA-258 NYroWFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNEDPxE1? MXK5OkBp M4q1T2ROW09? NVzrTVFIUUN3ME2wMlE{OiEQvF2= MY[yNVQ1QDV7MR?=
COG-E-352 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqwVHlMOTBizszN NVTyd4syQTZiaB?= NXPWcYFMTE2VTx?= NGGwWXdKSzVyPUCuNFQ{KM7:TR?= MYqyNVQ1QDV7MR?=
CHLA-90 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETofHUyOCEQvF2= M320WFk3KGh? Mm\CSG1UVw>? MV;JR|UxRTBwME[xJO69VQ>? NHfHTWwzOTR2OEW5NS=>
CHLA-119 NYq3OJJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOxRYl{OTBizszN M1Tne|k3KGh? M{jBXmROW09? MXjJR|UxRTBwMEKyJO69VQ>? MWCyNVQ1QDV7MR?=
CHLA-122 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfVVncyOCEQvF2= NX3te4szQTZiaB?= NETyXXRFVVOR MVPJR|UxRTBwMEG5JO69VQ>? NULXe4NGOjF2NEi1PVE>
CHLA-136 NI[yN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWxNEDPxE1? MnnWPVYhcA>? NGLjUHNFVVOR NFzOXXBKSzVyPUCuNFM6KM7:TR?= Ml7aNlE1PDh3OUG=
CHLA-140 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXlb4IyOCEQvF2= MWm5OkBp Mo\iSG1UVw>? M4DNbGlEPTB;MD6wNlYh|ryP M{HRbVIyPDR6NUmx
LA-N-6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjDTWoyOCEQvF2= M{Ow[Fk3KGh? MkCwSG1UVw>? MlHWTWM2OD1yLkC1OEDPxE1? MYmyNVQ1QDV7MR?=
NB-1643 NXG4SHJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jhfFExKM7:TR?= NIWzfnM6PiCq Mn3RSG1UVw>? NWr0OHVWUUN3ME2wMlA{PyEQvF2= M3:3XlIyPDR6NUmx
NB-EBc1 M{LiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPlWmgyOCEQvF2= MWW5OkBp NUPTc2ZTTE2VTx?= M3ewUWlEPTB;MD6wOVAh|ryP M3XJe|IyPDR6NUmx
SK-N-BE-1 M4rvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;YbFQyOCEQvF2= M2Lt[|k3KGh? NH:zc21FVVOR M4PkemlEPTB;MD6wNlgh|ryP NX[1VopEOjF2NEi1PVE>
SK-N-BE-2 NF7VVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKxNEDPxE1? NVvrflEzQTZiaB?= M2rCO2ROW09? MYTJR|UxRTBwMEO2JO69VQ>? NXHFO2lpOjF2NEi1PVE>
SMS-KAN NEfZXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrCNVAh|ryP NI\MSZA6PiCq MVrEUXNQ NYfQXId3UUN3ME2wMlA{PCEQvF2= MXqyNVQ1QDV7MR?=
SMS-KANR NH;QVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXiNXByOTBizszN MWO5OkBp NV[4emVMTE2VTx?= NHjOZYtKSzVyPUCuNFI3KM7:TR?= MnrENlE1PDh3OUG=
SMS-KCN NYTQSY55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELhZVkyOCEQvF2= NWmxboh{QTZiaB?= NU\G[5dpTE2VTx?= MYTJR|UxRTBwMEG5JO69VQ>? M{DLelIyPDR6NUmx
SMS-KCNR NF;TN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnPSXhjOTBizszN Mm\2PVYhcA>? NXTMTHVETE2VTx?= NVPQZoh[UUN3ME2wMlAyOCEQvF2= NV\tW29COjF2NEi1PVE>
SMS-LHN NXjkTZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjWV4EyOCEQvF2= MX65OkBp NFTMeWpFVVOR NEPmW|hKSzVyPUCuNFMzKM7:TR?= MnK5NlE1PDh3OUG=
SMS-MSN MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPSVW56OTBizszN NFK4SlM6PiCq M2nkNGROW09? MYLJR|UxRTBwMEKyJO69VQ>? NUXKO4RFOjF2NEi1PVE>
SMS-SAN NHT0e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrydW4yOCEQvF2= NIHS[lc6PiCq NUKzXYMyTE2VTx?= MoX5TWM2OD1yLkCyNEDPxE1? MoTFNlE1PDh3OUG=
Granta-4 NUTPRoNrS3m2b4TvfIlkKEG|c3H5 NIm0UGIyOCEQvF2= NEnMbVQ4KGR? M2G1NGlEPTB;MD6wOFAh|ryP MnvjNlEzQTF6Nke=
DB M3zreWN6fG:2b4jpZ{BCe3OjeR?= NEjGR24yOCEQvF2= NFXKcYg4KGR? MXTJR|UxRTBwMESyJO69VQ>? MXSyNVI6OTh4Nx?=
RL NH\nNW9EgXSxdH;4bYMhSXO|YYm= NWHXW3pzOTBizszN MnX0O{Bl M3roW2lEPTB;MD6wNVUh|ryP M2DwUlIyOjlzOE[3
K562 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCxNEDPxE1? MmnXPVYhcA>? NXjWXmVoUUN3ME2wMlA5PyEQvF2= MWqyNVA6OTZ|Mx?=
LAMA-84 M4Xmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\y[IdQOTBizszN Mn;EPVYhcA>? NXfmZnFFUUN3ME2wMlA2PyEQvF2= MonWNlExQTF4M{O=
MM15 NEHoVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWOEDPxE1? NGfBO2E4OiCq MVzEUXNQ NWK0PYl7UUN3ME2wMlE{KM7:TR?= MnO0NlA{QDJ6NES=
OPM1 NF7OcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnjS|c1KM7:TR?= NVXiclBDPzJiaB?= NWXYNJkxTE2VTx?= NU\RbXZ5UUN3ME2wMlA{KM7:TR?= M4PPVVIxOzh{OES0
RPM1 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:0JO69VQ>? MVm3NkBp NED2d4hFVVOR MX\JR|UxRTFyLkOyJO69VQ>? MnrMNlA{QDJ6NES=
INA6 NHv1SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvvOEDPxE1? NFfYUmU4OiCq NHflR3VFVVOR NXfSdnJDUUN3ME2wMlAxOiEQvF2= NHS4Z5EzODN6Mki0OC=>
OPM2 NELtTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;USpc1KM7:TR?= MY[3NkBp MknrSG1UVw>? NYLieWtvUUN3ME20MlM4KM7:TR?= MkLzNlA{QDJ6NES=
MM1R MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjBUoY1KM7:TR?= M2\n[|czKGh? NEHjSVVFVVOR MYPJR|UxRTFwNkig{txO MVOyNFM5Ojh2NB?=
DOX40 M2XUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC2N5U1KM7:TR?= MmTvO|IhcA>? MWfEUXNQ M{HrTGlEPTB;NT60PEDPxE1? NE\6[IkzODN6Mki0OC=>
LR5 MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH4OEDPxE1? MmD2O|IhcA>? M1i5WGROW09? M{m3SGlEPTB;Mj61N{DPxE1? MXyyNFM5Ojh2NB?=
U266 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj5OEDPxE1? M1XQRlczKGh? NGfHWVNFVVOR NGflXG1KSzVyPUGuOFMh|ryP NWm1[3I3OjB|OEK4OFQ>
RD NUfwdXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z3PVExKM7:TR?= MYq5OkBp NGXkbGpKSzVyPUCuNlI5KM7:TR?= NF30TnAzODFyOEOzPC=>
Rh41 M3exRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f3SlExKM7:TR?= M1\xNVk3KGh? MU\JR|UxRTBwMEmwJO69VQ>? NYf5eoUxOjBzMEizN|g>
Rh30 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxNEDPxE1? NGjvW246PiCq MmS4TWM2OD1yLkKzNEDPxE1? NX;3OYd1OjBzMEizN|g>
BT-12 NGHzdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTFSVF1OTBizszN NWexSo8yQTZiaB?= M3jXXWlEPTB;MD6wOlAh|ryP NXrHbngyOjBzMEizN|g>
CHLA-266 MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW5UI8yOCEQvF2= NUjtSXZPQTZiaB?= NV3nTnFFUUN3ME2wMlA4OiEQvF2= NIHWd3gzODFyOEOzPC=>
TC-71 M2n6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCxNEDPxE1? NYfmfmdFQTZiaB?= MX7JR|UxRTBwMUCyJO69VQ>? MXKyNFExQDN|OB?=
SJ-GBM2 NE\pSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDiTnd7OTBizszN NYXkSJBCQTZiaB?= NXXodJB[UUN3ME2wMlA2OCEQvF2= MUmyNFExQDN|OB?=
NALM-6 NEnlVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfncIlFOTBizszN NEjne2o6PiCq NH;nV3dKSzVyPUCuNFYzKM7:TR?= MkLlNlAyODh|M{i=
COG-LL-317 NYfDcWtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmxNEDPxE1? NWfUdJZ6QTZiaB?= M1iyRmlEPTB;MD6wOFch|ryP Mnu5NlAyODh|M{i=
RS4-11 M3TLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\WNlExKM7:TR?= NGO5NIU6PiCq NHiySVhKSzVyPUCuNFE5KM7:TR?= NFvwcGszODFyOEOzPC=>
MOLT-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO3dmhsOTBizszN M1X6Zlk3KGh? NGOxe3lKSzVyPUCuNFI3KM7:TR?= NGL1TnQzODFyOEOzPC=>
CCRF-CEM NHX5O3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPsZ|dqOTBizszN NXHMUohzQTZiaB?= NXT4dHlpUUN3ME2wMlA6PCEQvF2= NXPDTnNZOjBzMEizN|g>
Kasumi-1 NFrzeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxNEDPxE1? M3y5SVk3KGh? MlT0TWM2OD1yLkGwN{DPxE1? NUDVZ3duOjBzMEizN|g>
Karpas-299 NUfRZmV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNEDPxE1? Mn7YPVYhcA>? NUXrcWZoUUN3ME2wMlA{QCEQvF2= NFjlVWozODFyOEOzPC=>
Ramos-RA1 NHL2OZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUexNEDPxE1? NHXCdGg6PiCq NVvNVIpVUUN3ME2wMlEzPyEQvF2= NFzLWHkzODFyOEOzPC=>

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
15% Captisol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Related Antibodies

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID